RSS

National Institute for Health and Care Excellence (NICE)

Following a series of papers, published in The Lancet and featuring contributions from Professor Martin Underwood of Warwick Medical School, the NHS has published recommended changes to the treatment of low back pain. more

News

London-based scientists have found a new blood test that may be able to quickly predict if a female patient is responding to the breast cancer drug, palbociclib, earlier that is possible with currently available tests. more

Technology

A final appraisal determination (FAD) has been issued by the National Institute for Health and Care Excellence (NICE), recommending routine NHS use of avelumab for the treatment of adults in England, Wales and Northern Ireland with mMCC more

News

Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication more

News

NHS England has revealed that thousands of patients have benefited from the new CDF and as a result of discounts it has secured on eight treatments, savings of around £140 million should be generated over the course of the next five years more

News

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. more

News

Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. more

News

A new statement has been released based on a decision of the Board of the Association of the British Pharmaceutical Industry (ABPI) that it will not appeal the outcome of its judicial review application versus NICE more

News

Opdivo, also known as nivolumab, will now be available to NHS patients suffering from lung cancer as the drug’s manufacturer, Bristol-Myers Squibb, offers the National Institute for Health and Care Excellence (NICE) a new cancer drugs fund (CDF) deal more

News

A new severe asthma treatment, Reslizumab, has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE). more

Technology

The Association of the British Pharmaceutical Industry (ABPI) has confirmed its application for a Judicial Review over the new procedures, from NICE, to restrict access to cost-effective medicines more

News

NHS England has struck a deal with Roche and endorsed by the National Institute for Health and Care Excellence (NICE) to make the breast cancer drug Kadcyla available for routine use on the NHS. more

News

Eli Lilly and Company has announced that the National Institute for Health and Care Excellence (NICE) has recommended olaratumab (Lartruvo▼) in combination with doxorubicin as a treatment for advanced soft tissue sarcoma in adults more

News

Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the NHS for free for up to five months until a final decision by NICE is made. more

News

A survey of leading pharmaceutical businesses in the UK has led to a stark warning about a potential decrease in access to new medicines in the UK. more

News

GP and pharmaceuticals lawyer Dr Sam Samaratunga on the proposed changes to the UK market access for medicines more

News